|
1
|
Wojciechowska U, Didkowska J and Zatoński
W: Malignant neoplasms. Cancer in Poland in 2012. Oncology Centre -
Marie Curie Institute, . Warszawa: pp. 11–25. 2012
|
|
2
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar
|
|
3
|
Travis WD, Travis LB and Devesa SS: Lung
cancer. Cancer. 75(Suppl): 191–202. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Travis WD, Brambilla E, Müller-Hermelink
HK and Harris CC: Tumours of the lung. WHO Classification Pathology
and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. IARC
Press; pp. 9–122. 2004
|
|
5
|
Kathuria H, Gesthalter Y, Spira A, Brody
JS and Steiling K: Updates and controversies in the rapidly
evolving field of lung cancer screening, early detection, and
chemoprevention. Cancers (Basel). 6:1157–1179. 2014. View Article : Google Scholar
|
|
6
|
Zabarovsky ER, Lerman MI and Minna JD:
Tumor suppressor genes on chromosome 3p involved in the
pathogenesis of lung and other cancers. Oncogene. 21:6915–6935.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ohta M, Inoue H, Cotticelli MG, Kastury K,
Baffa R, Palazzo J, Siprashvili Z, Mori M, McCue P, Druck T, et al:
The FHIT gene, spanning the chromosome 3p14.2 fragile site and
renal carcinoma-associated t(3;8) breakpoint, is abnormal in
digestive tract cancers. Cell. 84:587–597. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Semba S, Trapasso F, Fabbri M, McCorkell
KA, Volinia S, Druck T, Iliopoulos D, Pekarsky Y, Ishii H, Garrison
PN, et al: Fhit modulation of the Akt-survivin pathway in lung
cancer cells: Fhit-tyrosine 114 (Y114) is essential. Oncogene.
25:2860–2872. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Weiske J, Albring KF and Huber O: The
tumor suppressor Fhit acts as a repressor of beta-catenin
transcriptional activity. Proc Natl Acad Sci USA. 104:20344–20349.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Siprashvili Z, Sozzi G, Barnes LD, McCue
P, Robinson AK, Eryomin V, Sard L, Tagliabue E, Greco A, Fusetti L,
et al: Replacement of Fhit in cancer cells suppresses
tumorigenicity. Proc Natl Acad Sci USA. 94:13771–13776. 1997.
View Article : Google Scholar
|
|
11
|
Roz L, Gramegna M, Ishii H, Croce CM and
Sozzi G: Restoration of fragile histidine triad (FHIT) expression
induces apoptosis and suppresses tumorigenicity in lung and
cervical cancer cell lines. Proc Natl Acad Sci USA. 99:3615–3620.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fong KM, Biesterveld EJ, Virmani A,
Wistuba I, Sekido Y, Bader SA, Ahmadian M, Ong ST, Rassool FV,
Zimmerman PV, et al: FHIT and FRA3B 3p14.2 allele loss are common
in lung cancer and preneoplastic bronchial lesions and are
associated with cancer-related FHIT cDNA splicing aberrations.
Cancer Res. 57:2256–2267. 1997.PubMed/NCBI
|
|
13
|
Pichiorri F, Okumura H, Nakamura T,
Garrison PN, Gasparini P, Suh SS, Druck T, McCorkell KA, Barnes LD,
Croce CM, et al: Correlation of fragile histidine triad (Fhit)
protein structural features with effector interactions and
biological functions. J Biol Chem. 284:1040–1049. 2009. View Article : Google Scholar :
|
|
14
|
Saldivar JC, Bene J, Hosseini SA, Miuma S,
Horton S, Heerem NA and Huebner K: Characterization of the role of
Fhit in suppression of DNA damage. Adv Biol Regul. 53:77–85. 2013.
View Article : Google Scholar :
|
|
15
|
Wang HL, Zhou PY, Liu P and Zhang Y:
Abnormal FHIT protein expression may be correlated with poor
prognosis in gastric cancer: A meta-analysis. Tumour Biol.
35:6815–6821. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Joannes A, Bonnomet A, Bindels S, Polette
M, Gilles C, Burlet H, Cutrona J, Zahm JM, Birembaut P and
Nawrocki-Raby B: Fhit regulates invasion of lung tumor cells.
Oncogene. 29:1203–1213. 2010. View Article : Google Scholar
|
|
17
|
Toledo G, Sola JJ, Lozano MD, Soria E and
Pardo J: Loss of FHIT protein expression is related to high
proliferation, low apoptosis and worse prognosis in non-small-cell
lung cancer. Mod Pathol. 17:440–448. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kim JS, Kim JW, Han J, Shim YM, Park J and
Kim DH: Cohypermethylation of p16 and FHIT promoters as a
prognostic factor of recurrence in surgically resected stage I
non-small cell lung cancer. Cancer Res. 66:4049–4054. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
American Joint Committee on Cancer Staging
according to the IASLC Staging Project. 7th edition. Cancer. 2010,
http://cancerstaging.org/references-tools/quickreferences/documents/lungmedium.pdf.
|
|
20
|
Herman JG, Graff JR, Myöhänen S, Nelkin BD
and Baylin SB: Methylation-specific PCR: A novel PCR assay for
methylation status of CpG islands. Proc Natl Acad Sci USA.
93:9821–9826. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Feltus FA, Lee EK, Costello JF, Plass C
and Vertino PM: Predicting aberrant CpG island methylation. Proc
Natl Acad Sci USA. 100:12253–12258. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li LC and Dahiya R: MethPrimer: Designing
primers for methylation PCRs. Bioinformatics. 18:1427–1431. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sozzi G, Tornielli S, Tagliabue E, Sard L,
Pezzella F, Pastorino U, Minoletti F, Pilotti S, Ratcliffe C,
Veronese ML, et al: Absence of Fhit protein in primary lung tumors
and cell lines with FHIT gene abnormalities. Cancer Res.
57:5207–5212. 1997.PubMed/NCBI
|
|
24
|
Sozzi G, Sard L, De Gregorio L, Marchetti
A, Musso K, Buttitta F, Tornielli S, Pellegrini S, Veronese ML,
Manenti G, et al: Association between cigarette smoking and FHIT
gene alterations in lung cancer. Cancer Res. 57:2121–2123.
1997.PubMed/NCBI
|
|
25
|
Sozzi G, Pastorino U, Moiraghi L,
Tagliabue E, Pezzella F, Ghirelli C, Tornielli S, Sard L, Huebner
K, Pierotti MA, et al: Loss of FHIT function in lung cancer and
preinvasive bronchial lesions. Cancer Res. 58:5032–5037.
1998.PubMed/NCBI
|
|
26
|
Zhao P, Li XY and Chen LZ: Loss of fragile
histidine triad expression and metastasis in breast cancer. Ai
Zheng. 21:668–670. 2002.(In Chinese). PubMed/NCBI
|
|
27
|
Bekar A, Ceçener G, Tunca B, Guler G,
Egeli U and Tolunay S: Investigation of mutations and expression of
the FHIT gene in Turkish patients with brain metastases derived
from non-small cell lung cancer. Tumori. 93:604–607. 2007.
|
|
28
|
Suh SS, Yoo JY, Cui R, Kaur B, Huebner K,
Lee TK, Aqeilan RI and Croce CM: FHIT suppresses
epithelial-mesenchymal transition (EMT) and metastasis in lung
cancer through modulation of microRNAs. PLoS Genet.
10:e10046522014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Song X, Tian Z, Wang S, Peng Z and Feng J:
Restoration of fragile histidine triad (FHIT) expression inhibits
cell growth and induces apoptosis in cutaneous T-cell lymphoma cell
line. Cancer Invest. 28:1019–1023. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zanesi N, Fidanza V, Fong LY, Mancini R,
Druck T, Valtieri M, Rüdiger T, McCue PA, Croce CM and Huebner K:
The tumor spectrum in FHIT-deficient mice. Proc Natl Acad Sci USA.
98:10250–10255. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Geradts J, Fong KM, Zimmerman PV and Minna
JD: Loss of Fhit expression in non-small-cell lung cancer:
Correlation with molecular genetic abnormalities and
clinicopathological features. Br J Cancer. 82:1191–1197. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Pavelić K, Krizanac S, Cacev T, Hadzija
MP, Radosević S, Crnić I, Levanat S and Kapitanović S: Aberration
of FHIT gene is associated with increased tumor proliferation and
decreased apoptosis-clinical evidence in lung and head and neck
carcinomas. Mol Med. 7:442–453. 2001.
|
|
33
|
Feng Q, Hawes SE, Stern JE, Wiens L, Lu H,
Dong ZM, Jordan CD, Kiviat NB and Vesselle H: DNA methylation in
tumor and matched normal tissues from non-small cell lung cancer
patients. Cancer Epidemiol Biomarkers Prev. 17:645–654. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tomizawa Y, Nakajima T, Kohno T, Saito R,
Yamaguchi N and Yokota J: Clinicopathological significance of Fhit
protein expression in stage I non-small cell lung carcinoma. Cancer
Res. 58:5478–5483. 1998.PubMed/NCBI
|
|
35
|
Tseng JE, Kemp BL, Khuri FR, Kurie JM, Lee
JS, Zhou X, Liu D, Hong WK and Mao L: Loss of Fhit is frequent in
stage I non-small cell lung cancer and in the lungs of chronic
smokers. Cancer Res. 59:4798–4803. 1999.PubMed/NCBI
|
|
36
|
Lindskog C, Edlund K, Mattsson JS and
Micke P: Immunohistochemistry-based prognostic biomarkers in NSCLC:
Novel findings on the road to clinical use? Expert Rev Mol Diagn.
15:471–490. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Marchetti A, Pellegrini S, Bertacca G,
Buttitta F, Gaeta P, Carnicelli V, Nardini V, Griseri P, Chella A,
Angeletti CA, et al: FHIT and p53 gene abnormalities in
bronchioloalveolar carcinomas. Correlations with
clinicopathological data and K-ras mutations. J Pathol.
184:240–246. 1998. View Article : Google Scholar : PubMed/NCBI
|
